Company(ies): Syntax Pharmaceuticals
Principal Therapy Area: Cancer
Entinostat is a novel, oral inhibitor of class I histone deacetylases (HDAC), key enzymes that alter the structure of chromatin to control gene expression. Designed to selectively target the HDAC isoforms most relevant to the biology of tumours, entinostat can specifically reactivate genes in cells where cancers have modified epigenetic control over the patterns operating in normal cells. This aberrant gene expression can result in reversible, epigenetically-based drug tolerance.
Syndax Pharmaceuticals is using a combination approach with entinostat to epigenetically modulate the development of drug tolerance to important classes of cancer drugs.
Use this Cancer Drug Futures report to analyse key drivers and dampeners of success
An extensive review of the factors which can affect this product's clinical and commercial performance. Each drug report provides and covers…
What you get
A copy of the Cancer Drug Futures report(s) in print or pdf as you wish
Are you interested in more than one product, indication or therapy area?
Why not build a specific drug futures library and save money!
We appreciate that some customers will need to review many products. That is why, if you buy more than 5 Cancer Drug Futures reports of your choice, we can arrange
Customers focusing on specific disease areas can benefit from buying our cost-effective Cancer Drug Futures collections. Collections are available for the following cancer sectors:
For further information on the products covered, discounts, distribution or a demonstration, please click on the link for firstname.lastname@example.org